MedTrace Logo

Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

NCT04189952 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2025-05-31

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test a combination treatment of acalabrutunib when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) to evaluate if it will be able to improve durable responses and cure some patients.

Conditions

Interventions

DRUG

Acalabrutinib

Acalabrutinib 100 mg capsules taken by mouth every 12 hours (PO BID), for a total of 2 daily doses on Days 1 to 21 of each cycle.

DRUG

Rituximab

Rituximab 375 mg/m2 administered intravenously (IV) on Day 1 of each cycle.

DRUG

Ifosfamide

Ifosfamide 5g/m2 administered intravenously (IV) over 24 hours on Day 2 of each cycle.

DRUG

Carboplatin

Carboplatin Area Under the Concentration time Curve (AUC) 5 IV administered intravenously (IV) on Day 2 of each cycle.

DRUG

Etoposide

Etoposide 100 mg/m2 administered intravenously (IV) on Days 1, 2 and 3 of each cycle.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • University of Miami

    lead OTHER

Principal Investigators

  • Craig Moskowitz, MD · University of Miami

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-22
Primary Completion
2021-06-30
Completion
2022-03-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04189952 on ClinicalTrials.gov